Heartflow, Inc. (NASDAQ:HTFL) Sees Significant Growth in Short Interest

Heartflow, Inc. (NASDAQ:HTFL) was the recipient of a significant increase in short interest during the month of January. As of January 30th, there was short interest totaling 4,951,283 shares, an increase of 42.4% from the January 15th total of 3,476,809 shares. Based on an average daily trading volume, of 843,019 shares, the short-interest ratio is presently 5.9 days. Currently, 5.8% of the company’s shares are sold short. Currently, 5.8% of the company’s shares are sold short. Based on an average daily trading volume, of 843,019 shares, the short-interest ratio is presently 5.9 days.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on HTFL shares. Wells Fargo & Company started coverage on Heartflow in a research report on Wednesday, January 28th. They set an “overweight” rating and a $38.00 price target on the stock. Canaccord Genuity Group boosted their target price on shares of Heartflow from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Weiss Ratings reiterated a “sell (d)” rating on shares of Heartflow in a research note on Monday, December 29th. JPMorgan Chase & Co. boosted their price objective on shares of Heartflow from $36.00 to $40.00 and gave the stock an “overweight” rating in a research note on Thursday, November 13th. Finally, Stifel Nicolaus raised their target price on shares of Heartflow from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.50.

Heartflow Trading Down 8.1%

Shares of HTFL stock opened at $20.66 on Tuesday. The company has a market capitalization of $1.76 billion and a PE ratio of -11.41. Heartflow has a 1 year low of $20.13 and a 1 year high of $41.22. The company has a 50 day moving average of $29.83.

Insider Buying and Selling

In related news, major shareholder Bain Capital Life Sciences Inv sold 2,000,000 shares of the stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $28.05, for a total transaction of $56,100,000.00. Following the completion of the sale, the insider directly owned 10,448,158 shares of the company’s stock, valued at approximately $293,070,831.90. This represents a 16.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Julie A. Cullivan sold 8,000 shares of the firm’s stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $27.32, for a total transaction of $218,560.00. Following the sale, the director owned 36,413 shares in the company, valued at approximately $994,803.16. The trade was a 18.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 2,030,562 shares of company stock valued at $56,938,113 over the last 90 days.

Hedge Funds Weigh In On Heartflow

Institutional investors have recently added to or reduced their stakes in the stock. Baillie Gifford & Co. bought a new stake in Heartflow during the third quarter valued at $101,182,000. New York State Common Retirement Fund acquired a new position in shares of Heartflow in the 3rd quarter valued at about $4,015,000. Emerald Mutual Fund Advisers Trust bought a new stake in shares of Heartflow during the 3rd quarter valued at about $4,418,000. Board of Trustees of The Leland Stanford Junior University acquired a new stake in Heartflow during the third quarter worth approximately $10,510,000. Finally, Lisanti Capital Growth LLC bought a new stake in Heartflow in the third quarter worth approximately $982,000.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.